Application of hirudin as medicine for preventing and treating hyperuricemia

A technology of hyperuricemia and hirudin, which can be used in drug combinations, medical preparations containing active ingredients, antipyretics, etc., can solve problems such as suboptimal effects

Inactive Publication Date: 2018-05-08
广西卫生职业技术学院
View PDF9 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0014] From the literature retrieved, we can understand that hirudin is not used as a drug for treating gout in the prior art, and only hirudin is used as a drug for treating cardiovascular and cerebrovascular diseases, cerebral apoplexy, and insulin-resistant diabetes in the prio

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hirudin as medicine for preventing and treating hyperuricemia
  • Application of hirudin as medicine for preventing and treating hyperuricemia
  • Application of hirudin as medicine for preventing and treating hyperuricemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1: Effect of Hirudin on Serum Uric Acid in Hypoxanthine-Induced Hyperuricemia Mice

[0036] Materials: hirudin, allopurinol tablets, hypoxanthine, uric acid kit.

[0037] Experimental animals: Kunming mice.

[0038] 1. Experimental method

[0039] Select 70 Kunming mice with a body weight of 18-22 g, male, and randomly divide them into 10 groups, with 10 mice in each group, that is, the control group and the model group, and the positive drug allopurinol (0.01 g.kg -1 ) group, Phnom Penh leech dry powder (2.0 g herbs.kg -1 ) group, high, medium and low doses of hirudin (0.8, 0.4, 0.2 g herbs.kg -1 )Group. Each group was administered ig once a day, and the control group and model group were given equal volumes of distilled water ig for 12 consecutive days. Except for the control group, each group received ip hypoxanthine 600 mg.kg 1 hour after the last administration -1 After 1 h, the blood was collected from the eyeball, centrifuged at 3000 r / min for 10 mi...

Embodiment 2

[0046] Example 2: Effect of Hirudin on Serum Uric Acid in Hyperuricemia Mice Induced by Potassium Oxonate

[0047] Materials: hirudin, allopurinol tablets, potassium oxonate, uric acid kit.

[0048] Experimental animals: Kunming mice.

[0049] 1. Experimental method

[0050] Select 70 Kunming mice with a body weight of 18-22 g, male, and randomly divide them into 10 groups, with 10 mice in each group, that is, the control group and the model group, and the positive drug allopurinol (0.005 g.kg -1 ) group, Phnom Penh leech dry powder (2.0 g herbs.kg -1 ) group, high, medium and low doses of hirudin (0.8, 0.4, 0.2 g herbs.kg -1 )Group. Each group was administered ig once a day, and the control group and model group were given equal volumes of distilled water ig for 45 consecutive days. Except for the control group, mice in each group were intragastrically administered 2.5 g.kg -1 Potassium oxonate in body weight, replicating the hyperuricemia model. One hour after the las...

Embodiment 3

[0057] Example 3: Effect of hirudin on paw swelling of rats induced by microcrystalline sodium urate crystals (MSU)

[0058] Materials: hirudin, allopurinol tablets, microcrystalline sodium urate crystals.

[0059] Experimental animals: Wistar male rats.

[0060] 1. Experimental method

[0061] Preparation of MSU: Put 5 g of uric acid in 1000 mL of boiling water, adjust the pH to 7.4 with NaOH, and heat to 95°C. Cool at room temperature and stir gently, filter to obtain MSU, sterilize MSU at 200°C, and prepare a 100 mg / mL suspension with sterile saline immediately before use.

[0062] Select 50 Wistar male rats with a body weight of 180~220g, and randomly divide them into 5 groups, 10 in each group, i.e. normal control group, model group, positive drug allopurinol tablet group (10mg / kg), hirudin high and low ( 800, 200 mg.kg -1 ) dose group. Oral administration, once a day, the normal control group and the model group were given equal volume of distilled water by intragas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of hirudin as a medicine for preventing and treating hyperuricemia, and discloses novel application of the hirudin for preparing a medicine for preventing and treating the hyperuricemia and diseases caused by the hyperuricemia; Kunming mice are induced by hypoxanthine and potassium oxonate to establish hyperuricemia models, and intervention effects of the hirudin on the hyperuricemia are observed. Research results show that the use of the hirudin for 12 consecutive days in the Kunming mice significantly reduces a serum uric acid level in hypoxanthine-induced hyperuricemia mice; the hirudin can also be used to prepare medicines for the hyperuricemia and the diseases caused by the hyperuricemia: obstructive sleep apnea and/or menopause syndrome, or hypertension, hyperlipidemia, atherosclerosis, obesity, insulin resistance, nephropathy, inflammation, infectious diseases, tumor lysis syndrome and other diseases. New application of the hirudin is openedup.

Description

technical field [0001] The invention relates to the technical field of application of hirudin, in particular to the application of hirudin as a drug for preventing and treating hyperuricemia and diseases caused by it. Background technique [0002] Uric acid is 2,6,8-purine trioxide, which is the end product of purine metabolism. Due to the lack of uric acid decomposing enzymes in the human body, uric acid, the end product of purine metabolism, cannot be further decomposed into allantoin, making hyperuricemia and gout a relatively special human disease. Recent studies have shown that hyperuricemia is not only the most important biochemical basis of gout, but also associated with hypertension, hyperlipidemia, atherosclerosis, obesity, insulin resistance, kidney disease, inflammation, the severity of infectious diseases, tumor Dissolving syndrome, climacteric syndrome, organ transplantation complications and some intractable diseases (obstructive sleep apnea, primary Sjogren's...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/58A61P19/06A61P9/12A61P3/06A61P9/10A61P3/04A61P5/50A61P13/12A61P29/00A61P31/00A61P35/00A61P15/12A61P37/06A61P11/00A61P37/02
CPCA61K38/58
Inventor 刘喜华黄敏琪周维海
Owner 广西卫生职业技术学院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap